Related Experiment Video
Updated: Feb 16, 2026

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer
Thomas Regenbogen1, Ling Chen, Kathryn Trinkaus
1Division of Oncology, Washington University, St. Louis, MO, USA.
Background:
Treatment options for patients with refractory colorectal cancer are limited and typically provide a chance of only modest benefit. The goal of this study was to evaluate the benefit of inhibiting the JAK/STAT inflammatory pathway with single agent pacritinib in patients with metastatic refractory colorectal adenocarcinoma.
Methods:
A single arm institutional trial was initiated and enrolled patients with metastatic colorectal cancer refractory to at least two standard lines of treatment. Pacritinib 400 mg daily was administered orally continuously in 28 day cycles.
Results:
The trial was discontinued prior to reaching the planned accrual due to an FDA hold on pacritinib and a lack of treatment benefit. Eleven patients were enrolled and seven were evaluated for response. Median baseline C-reactive protein level was 12.1 (2.1-147) mg/L. One patient had stable disease at eight weeks by RECIST criteria and six progressed. There were no grade 4 or 5 adverse events while patients were on study. The grade 2 and lower AE events experienced were consistent with prior pacritinib trials.
Conclusions:
In seven evaluable patients there were no objective responses. The trial was discontinued prior to completing planned accrual based on a low likelihood that the progression free survival goal of 4 months would be met.
Insights
Pacritinib, a JAK/STAT inhibitor, showed no objective responses in refractory colorectal cancer patients. The trial was halted due to limited benefit and an FDA hold, indicating poor efficacy for this patient group.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Limited treatment options exist for refractory colorectal cancer.
- The JAK/STAT pathway is implicated in cancer inflammation.
- Pacritinib targets the JAK/STAT pathway.
Purpose of the Study:
- To evaluate pacritinib's efficacy in metastatic refractory colorectal adenocarcinoma.
- To assess the inhibition of the JAK/STAT pathway as a therapeutic strategy.
Main Methods:
- Single-arm institutional trial.
- Administered pacritinib 400 mg daily orally.
- Enrolled patients refractory to at least two prior treatments.
Main Results:
- Trial discontinued early due to FDA hold and lack of benefit.
- Seven patients evaluated; one had stable disease, six progressed.
- No objective responses observed; adverse events were grade 2 or lower.
Conclusions:
- Pacritinib demonstrated no objective responses in evaluable patients.
- Trial halted due to low likelihood of meeting progression-free survival goals.
- Further investigation of pacritinib in this setting is not supported.
More Related Videos
13:04In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
11:41Methods for Culturing Human Femur Tissue Explants to Study Breast Cancer Cell Colonization of the Metastatic Niche
Published on: March 15, 2015
Related Concept Videos
The JAK-STAT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Feedback Inhibition
The Colonization of Land
Assessing Body Temperature - Rectal
Follow these steps for rectal temperature assessment:
Step 1: Perform hand hygiene and don clean gloves to prevent cross-infection.
Step 2: Position the patient in a side-lying position to better visualize the rectal...
Enzyme Inhibition